Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.71 |
| ▸ | AHR | P35869 | 1/20 | 0.71 |
| ▸ | PLK1 | P53350 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28029090 | 0.86 | KDM4E (0.69) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL719242 | 0.86 | KDM4E (0.78) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL4775716 | 0.84 | KDM4E (0.71) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL22960371 | 0.83 | KDM4E (0.69) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL29502916 | 0.83 | KDM4E (1.00) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL585270 | 0.83 | KDM4E (1.00) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL30364386 | 0.83 | ALDH1A1 (0.62) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL27818818 | 0.82 | KDM4E (0.64) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL31475455 | 0.82 | KDM4E (0.68) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL10897719 | 0.82 | PTGS2 (0.59) | KDM4EAHRPLK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| WO-2009085256-A1 | ANTI-HIV COMPOUNDS | PANACOS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| US-5596100-A | CYCLOADDITION REACTION OF SUBSTITUTED IODOBENZENES WITH ALKYNES | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | KDM4E 4266/4885AHR 1926/4885PLK1 4366/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | KDM4E 4275/4885AHR 1933/4885PLK1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.